Anixa Biosciences Inc. [NASDAQ: ANIX] closed the trading session at $3.14 on 12/10/20. The day’s price range saw the stock hit a low of $2.85, while the highest price level was $5.40. The company report on December 1, 2020 that Anixa Biosciences Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology.
Anixa to Host a Conference Call Thursday, December 3, 2020, 1:15 p.m. PT to Discuss Program.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced that it has entered into a license agreement with Cleveland Clinic for exclusive, world-wide rights to an innovative ovarian cancer vaccine technology.
The stocks have a year to date performance of -4.27 percent and weekly performance of 11.74 percent. The stock has been moved at 38.33 percent over the last six months. The stock has performed 56.22 percent around the most recent 30 days and changed 50.96 percent over the most recent 3-months.
If compared to the average trading volume of 190.50K shares, ANIX reached to a volume of 16858055 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Anixa Biosciences Inc. [ANIX]:
The Average True Range (ATR) for Anixa Biosciences Inc. is set at 0.38 The Price to Book ratio for the last quarter was 8.49, with the Price to Cash per share for the same quarter was set at 0.39.
ANIX stock trade performance evaluation
Anixa Biosciences Inc. [ANIX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.74. With this latest performance, ANIX shares gained by 56.22% in over the last four-week period, additionally plugging by 38.33% over the last 6 months – not to mention a drop of -18.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ANIX stock in for the last two-week period is set at 67.12, with the RSI for the last a single of trading hit 71.37, and the three-weeks RSI is set at 64.82 for Anixa Biosciences Inc. [ANIX]. The present Moving Average for the last 50 days of trading for this stock 2.42, while it was recorded at 2.96 for the last single week of trading, and 2.33 for the last 200 days.
Anixa Biosciences Inc. [ANIX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Anixa Biosciences Inc. [ANIX] shares currently have an operating margin of -4588.50 and a Gross Margin at -153.02. Anixa Biosciences Inc.’s Net Margin is presently recorded at -4658.82.
Return on Total Capital for ANIX is now -229.52, given the latest momentum, and Return on Invested Capital for the company is -218.31. Return on Equity for this stock declined to -218.31, with Return on Assets sitting at -182.81.
Reflecting on the efficiency of the workforce at the company, Anixa Biosciences Inc. [ANIX] managed to generate an average of -$1,455,882 per employee. Receivables Turnover for the company is 7.52 with a Total Asset Turnover recorded at a value of 0.04.Anixa Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.60 and a Current Ratio set at 7.60.
Earnings per share (EPS) analysis for Anixa Biosciences Inc. [ANIX] stock
With the latest financial reports released by the company, Anixa Biosciences Inc. posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 58.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ANIX.
Anixa Biosciences Inc. [ANIX]: Insider Ownership positions
There are presently around $6 million, or 7.70% of ANIX stock, in the hands of institutional investors. The top three institutional holders of ANIX stocks are: VANGUARD GROUP INC with ownership of 656,878, which is approximately -2.409% of the company’s market cap and around 5.40% of the total institutional ownership; UBS GROUP AG, holding 528,043 shares of the stock with an approximate value of $1.66 million in ANIX stocks shares; and QUBE RESEARCH & TECHNOLOGIES LTD, currently with $0.43 million in ANIX stock with ownership of nearly 414.345% of the company’s market capitalization.
Positions in Anixa Biosciences Inc. stocks held by institutional investors increased at the end of December and at the time of the December reporting period, where 10 institutional holders increased their position in Anixa Biosciences Inc. [NASDAQ:ANIX] by around 302,349 shares. Additionally, 9 investors decreased positions by around 72,754 shares, while 6 investors held positions by with 1,451,866 shares. The mentioned changes placed institutional holdings at 1,826,969 shares, according to the latest SEC report filing. ANIX stock had 6 new institutional investments in for a total of 178,558 shares, while 4 institutional investors sold positions of 41,024 shares during the same period.